Form 8-K - Current report:
SEC Accession No. 0000950170-24-109463
Filing Date
2024-09-26
Accepted
2024-09-26 06:33:37
Documents
21
Period of Report
2024-09-26
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K engn-20240926.htm   iXBRL 8-K 48860
2 EX-99.1 engn-ex99_1.htm EX-99.1 21841
3 EX-99.2 engn-ex99_2.htm EX-99.2 11915
4 GRAPHIC img7790613_0.jpg GRAPHIC 13114
5 GRAPHIC engn-ex99_2s1.jpg GRAPHIC 169645
6 GRAPHIC engn-ex99_2s2.jpg GRAPHIC 961257
7 GRAPHIC engn-ex99_2s3.jpg GRAPHIC 295783
8 GRAPHIC engn-ex99_2s4.jpg GRAPHIC 222251
9 GRAPHIC engn-ex99_2s5.jpg GRAPHIC 351746
10 GRAPHIC engn-ex99_2s6.jpg GRAPHIC 362695
11 GRAPHIC engn-ex99_2s7.jpg GRAPHIC 270914
  Complete submission text file 0000950170-24-109463.txt   3894521

Data Files

Seq Description Document Type Size
12 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT engn-20240926.xsd EX-101.SCH 47535
23 EXTRACTED XBRL INSTANCE DOCUMENT engn-20240926_htm.xml XML 6764
Mailing Address 4868 RUE LEVY, SUITE 220 SAINT-LAURENT A8 H4R 2P1
Business Address 4868 RUE LEVY, SUITE 220 SAINT-LAURENT A8 H4R 2P1 (514) 332-4888
enGene Holdings Inc. (Filer) CIK: 0001980845 (see all company filings)

EIN.: 000000000 | State of Incorp.: Z4 | Fiscal Year End: 1031
Type: 8-K | Act: 34 | File No.: 001-41854 | Film No.: 241326149
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)